Researchers Say Not All A-Fib Patients Need Anticoagulation

Share this content:
Researchers Say Not All A-Fib Patients Need Anticoagulation
Researchers Say Not All A-Fib Patients Need Anticoagulation

TUESDAY, Oct. 18, 2016 (HealthDay News) -- Some patients with atrial fibrillation who have implanted pacemakers or defibrillators may not always need anticoagulation, according to a study published online Oct. 17 in Circulation.

Steven Swiryn, M.D., a clinical professor of cardiology at the Feinberg School of Medicine at Northwestern University in Chicago, and colleagues looked at 37,531 electrograms from 5,379 patients over two years. All the participants took part in the RATE Registry (Registry of Atrial Tachycardia and Atrial Fibrillation Episodes), an ongoing study that follows patients with pacemakers or defibrillators.

The researchers found that patients who had only short bouts of atrial fibrillation -- estimated at 20 seconds or less -- were at no more risk for stroke or other cardiovascular complications than patients without atrial fibrillation.

"We knew that people with atrial fibrillation are at higher risk of stroke, but the next question was, how much atrial fibrillation?" Swiryn said in a news release from the American Heart Association. "Other studies have shown that prolonged episodes of atrial fibrillation pose a risk, but what about short ones? The answer until this study was 'no one knows.' Now we have good solid data that if all you have is short episodes of atrial fibrillation, the risk is so low that it doesn't warrant anticoagulants."

Several authors disclosed financial ties to pharmaceutical and medical device companies, including St. Jude Medical, which funded the RATE Registry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »